← All stories
Markets
Revolution pancreatic cancer drug should quickly become a blockbuster, analysts say
Rasonque’s $39,800 monthly list price surpassed Wall Street forecasts and led to rosier sales projections ahead of what one analyst described as a “historic” launch.
Covered by 1 outlet
All coverage · 1 article